Ceraxon 4ml/1000mg ampules №5

Pharmacological action

Pharmacodynamics
Tsitikolin, as a key precursor of ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action - helps to restore damaged cell membranes, inhibits the action of phospholipases, preventing excessive formation of free radicals and preventing cell death, affecting the mechanisms of apoptosis. In the acute phase of stroke reduces the amount of damaged tissue, improving cholinergic transmission. With traumatic brain injury reduces the duration of post-traumatic coma and the severity of neurological symptoms.
Tsitikolin observed during hypoxia improves symptoms such as memory impairment, emotional lability, lack of initiative, difficulty in performing daily activities and self care.
Effective in the treatment of cognitive, sensory and motor neurological disorders, degenerative and vascular etiology.

Pharmacokinetics
Since tsitikolin is a natural compound that is contained in the body, classical pharmacokinetic study can not be performed due to the complexity of the quantitative determination of exogenous and endogenous tsitikolina. In the pharmacokinetic study in healthy volunteers with a destination inside the labeled 14C-tsitikolina almost complete its absorption. Within 5 days after the appointment of the dose excreted in the feces less than 1% of the scheduled dose.

Statement

- Acute ischemic stroke.
- The recovery period of ischemic and hemorrhagic strokes.
- Head injury, acute and recovery period.
- Cognitive impairment in degenerative and vascular diseases of the brain.

Contraindications

Should not be prescribed to patients with vagotonia (predominance of parasympathetic tone of the autonomic nervous system) and with hypersensitivity to any component of the drug. Do not use in children younger than 18 years (due to lack of data).

Pregnancy and lactation

Controlled studies in pregnancy have been conducted. Although the evidence of risk to the fetus in the application of the drug has not been received, during pregnancy medication prescribed only if the expected benefit outweighs the potential risk.
In appointing Tseraksona lactating women should stop breast-feeding, because the data on the allocation of tsitikolina with human milk are not available.

Dosing regimen

Solution for intravenous and intramuscular

Intravenously in the form prescribed by slow intravenous injection (5 minutes) or intravenous drip (40 - 60 drops per minute) for stroke and traumatic brain injury in the acute period of 1000 - 2000 mg daily, depending on the severity of the disease within 3 -7 days with a subsequent transition to the intramuscular injection or ingestion. Intravenous and peroralnyi route of administration is preferable to intramuscular.
Intramuscular: 1-2 injections per day. When administered intramuscularly to avoid the reintroduction of the drug in the same place.

Oral solution

200 - 300 mg (2 - 3 ml) 3 times a day. (The drug is prescribed by the dosing syringe).

Side effect

Allergic reactions (rash, itching, anaphylactic shock), insomnia, headache, dizziness, agitation, tremors, numbness in the paralyzed limbs, nausea, decreased appetite, changes in liver enzymes, fever. In some cases Tserakson can stimulate the parasympathetic system, as well as provide short-term hypotensive effect.

Overdose

Given the low toxicity of the drug overdose cases were not described, even in case of exceeding the therapeutic dose.

Drug Interactions

Tsitikolin enhances the effects of L-digidroksifenilalanina.
Should not be prescribed in conjunction with drugs containing meklofenoksat.

Effects on ability to drive and operate with mechanisms
Tsitikolin no effect on the ability to drive vehicles and use machinery.

Shelf life

Store at temperatures not above 30 ° C in a place inaccessible to children. Shelf life 3 years. Do not use after expiration date printed on the packaging.